about
Retinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategiesCellular and molecular biology of small cell lung cancer: an overviewFrom Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung CancersOrigins, genetic landscape, and emerging therapies of small cell lung cancerRegulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapyOvine pulmonary adenocarcinoma: a large animal model for human lung cancerExposure of Human Lung Cells to Tobacco Smoke Condensate Inhibits the Nucleotide Excision Repair PathwayLipophilic bisphosphonates plus rapamycin: a deadly combination for KRAS-mutated lung adenocarcinomaMYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer.Long non-coding RNAs in cancer and development: where do we go from here?Splicing landscape of the eight collaborative cross founder strains.Inhibition of 11β-Hydroxysteroid Dehydrogenase Type II Suppresses Lung Carcinogenesis by Blocking Tumor COX-2 Expression as Well as the ERK and mTOR Signaling Pathways.The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasisTissue-specific tumorigenesis: context matters.Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle ClearanceTree shrew as a new animal model for the study of lung cancerTranscription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtypeDiscoidin domain receptor 2 signaling networks and therapy in lung cancer.Modeling the lung: Design and development of tissue engineered macro- and micro-physiologic lung models for research use.Non-small-cell lung cancers: a heterogeneous set of diseases.Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer.Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.Circulating tumor cells and CDX models as a tool for preclinical drug developmentProgress and prospects of early detection in lung cancer.Loss of the SWI/SNF ATPase subunits BRM and BRG1 drives lung cancer development.Evaluating the effectiveness of cancer drug sensitization in vitro and in vivo.Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.Small-cell lung cancer: what we know, what we need to know and the path forward.Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer.Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity.An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients.K-Ras(V14I) -induced Noonan syndrome predisposes to tumour development in mice.Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models.
P2860
Q26750380-938BFB66-F1D7-4A52-8CB0-AB134D86F75CQ26767029-13EC7C18-1A0E-41AD-B445-03D390D74393Q26771375-7260018F-F5B6-4432-966C-F3104DA658AAQ26798218-C779D0A5-81D7-4D5A-8E09-296EE4DC7BD5Q27310763-2ECB4BB3-5EBF-4739-BAC5-8989C9892499Q28069764-AADDB03A-EA59-45A1-BC78-FC94FD06C197Q28088774-1F615EE2-BE9F-4BEC-BB50-E1C3246A0BC7Q28552525-282DD0B4-7DF5-44B7-81A8-1AFABDE7BF82Q28606634-49D03A2D-D7E9-4442-B8F2-2511EC272C35Q33804675-8D019F3A-83C2-43AD-9C80-BE0D1938C35EQ34426010-EC40316F-633C-4D86-BEAC-A238A37C0A0DQ35016600-DC9D4478-BB68-44A2-BFB2-DCAE813CDF5DQ35061346-3DBEFBC6-2575-41DC-8DCC-1889AAD01A40Q35641880-42E9A0CB-5DA5-4172-9C2A-46F7D2B5D3BBQ35911414-D975B489-0738-492C-AECF-D142B04947CBQ35952716-22699580-8305-4EC9-AAC4-C85BEC96FE32Q36296335-E731953E-F5E5-4BE2-B301-D4FD7F8520A3Q36331953-8083F00E-CC04-4FFE-BA1D-7AA6F3A33B20Q36600153-1E17E8E7-5274-4B4E-A236-A88C46C91F08Q36640566-02662549-9815-491A-9F1A-1A7B6C232714Q37116260-0EE75D86-F226-4177-8A60-A5630948230FQ37525082-C1C3F15D-927D-488F-809B-C627F2E8BD14Q37710826-8D525560-9248-41E3-B1C6-F79872359BC8Q38211796-DAD48BB3-EACE-47A6-8061-1A1CFF455B01Q38223001-5993C787-CFAA-43EF-B6DC-D437DFBCCC0AQ38233321-05860798-44A7-4F83-B274-84CA6D9E947AQ38578968-887E1883-F9B6-4623-AE5E-0AE14B2B9716Q38622790-5B35D377-A20A-42D8-A87A-0214A538F3CDQ41605022-4B6698C7-0B59-4B01-83A8-B9104CEE7957Q42139806-858C9199-5A8C-4F11-9B69-0DD17920602FQ42330439-67CF7583-E24D-42BC-9744-82C341F2572CQ43181617-551A26C0-56FB-4332-B1A9-11386E6BB9F8Q47345427-EBE8390C-69FD-4A32-B8DB-9699A996B01CQ47595394-06D2241D-C79B-4A57-91D8-6EA6C37AB32DQ48001140-082E5A1C-2B3D-4E55-9188-CA3199BA8DA3Q50505775-8217A4FF-6601-496F-836E-E1C66080A03EQ52627783-5C8B3221-CF6F-4B49-A37C-2D8CDF06FE23Q53072915-FF4930AD-8DD9-4FC8-8855-18F16D001977Q53101926-6FCC67DC-FA87-4AF4-BA2B-C4A6E42DA149Q53702193-BB85FCC7-BB6E-45CC-99ED-969845A4F248
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mouse models for lung cancer
@en
type
label
Mouse models for lung cancer
@en
prefLabel
Mouse models for lung cancer
@en
P2860
P1433
P1476
Mouse models for lung cancer
@en
P2093
Anton Berns
Min-chul Kwon
P2860
P304
P356
10.1016/J.MOLONC.2013.02.010
P577
2013-02-19T00:00:00Z